Select Page

Manish Singh


Manish Singh, PhD, serves as Managing Director of Molecule Capital, LLC, a medical and technology focused fund. Previously, R. Manish Singh served as Chairman and CEO of Iovance Biotherapeutics, an immunotherapy company focused on multiple solid cancers and as CEO of ImmunoCellular Therapeutics, Ltd., where he was instrumental in developing a platform for dendritic cell-based vaccines targeting cancer stem cells.

Prior to that, Dr. Singh served as director at the venture capital firm California Technology Ventures, where he managed investments in a number of medical device and biotechnology firms while serving as a board director or observer for several of the firm’s portfolio companies. Earlier in his career, Dr. Manish Singh held various management and scientific positions at Cell Genesys, Chiron Corporation and Genetic Therapy, Inc. Dr. Singh holds an MBA from University of California Los Angeles and a PhD in chemical and biochemical engineering from the University of Maryland Baltimore County.  

During his time in graduate school, the new technology to manipulate genes of cells whether plants or animals or humans was just in the beginning stages. Dr. Manish Singh’s focus at that time was on designing new drug delivery systems for new medicines. He saw gene therapy as a way to fix diseases at the most fundamental level by changing the blue-print of the cells. Upon finishing his post-doctoral work at American Red Cross’s laboratory for blood research, Dr. Singh had two offers  for scientific positions. One was from Merck and second from a tiny company in Maryland called Genetic Therapy Inc. He was so passionate about gene therapy that he declined the Merck offer to join this little company.

“My goal is to create virtual companies that can build on significant innovations taking place in immunology today by combining risk capital, great people and innovative products.”

Dr. Manish Singh

Dr. Manish Singh's Specialties
  • Business Development
  • Product Development
  • Strategy
  • Financing Early Stage Companies

“Even though I started working in this field 23 years ago, only now we are starting to come close to being able to edit genes in a precise and direct manner. The new technology of CRISPR allows you to precisely make edits on the chromosomes which has huge implications for human diseases. My passion over the last 12 years has been on oncology and we have gone through several iterations of new technologies to crack this mystery. 30 years ago we had no idea how immune system becomes dysfunctional in cancer patients. Now we have developed several new drugs that allow the immune system to be set free in these patients. Our future goal should be  to design individualized treatments for these cancer patients that are potentially curative. I was to be a part of this revolution.”

Dr. Manish Singh

Scientific Advisory Board – Necessity or Waste of Money?

Life as a biotech entrepreneur is difficult and finding the right people is one of the, if not the, most important factors in making your company a success. Enlisting the right people is not limited to finding the perfect co-founder and start-up team members, but...
Read More

Running a Startup is a Team Sport – Choose Your Team Wisely

Biotech startups are in many ways different from high-tech startups, but one core aspect is common to them and indeed all startups: your early key hires are critical to your company’s success — or failure. Founding or joining a startup is a commitment rivaled in...
Read More

Licensing Technology for a Biotech Startup

Manish Singh and Tina Baumgartner Biotech companies are often based on great, exciting, innovative ideas. After that exhilarating first step to start a new company it gets a lot more practical quickly: the fledgling startup needs a solid fundament to survive, grow and...
Read More

How To Start A Successful Biotech Company

Legend has it that every self-respecting high-tech company was founded in a garage with its initial business plan written on the back on a napkin.  But how do biotech companies do it, given the lack of six digit lab equipment and appropriate biosafety levels in your...
Read More

When Does Gene Editing Cross the Line?

Would you believe me if I told you scientists could completely change the physical characteristics of an entire species by changing one small piece of DNA? It’s true, and it has been happening for the past 20 years or so. Although it did not work effectively at first,...
Read More